Shares of Exactech, Inc. (NASDAQ:EXAC) have received a consensus recommendation of “Hold” from the seven ratings firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and five have issued a hold recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $49.00.
EXAC has been the subject of several recent research reports. Zacks Investment Research cut shares of Exactech from a “hold” rating to a “sell” rating in a report on Wednesday, October 25th. Gabelli cut shares of Exactech from a “buy” rating to a “hold” rating in a report on Tuesday, October 24th. Robert W. Baird cut shares of Exactech from an “outperform” rating to a “neutral” rating and set a $42.00 target price for the company. in a report on Monday, October 23rd. ValuEngine cut shares of Exactech from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Finally, Sidoti cut shares of Exactech from a “buy” rating to a “neutral” rating in a report on Monday, October 23rd.
Institutional investors have recently modified their holdings of the stock. Highbridge Capital Management LLC purchased a new position in shares of Exactech during the third quarter worth $201,000. AMP Capital Investors Ltd purchased a new position in Exactech in the third quarter valued at $215,000. Citadel Advisors LLC purchased a new position in Exactech in the second quarter valued at $235,000. Voya Investment Management LLC purchased a new position in Exactech in the second quarter valued at $243,000. Finally, Paragon Capital Management Ltd purchased a new position in Exactech in the fourth quarter valued at $277,000. 60.11% of the stock is owned by hedge funds and other institutional investors.
Exactech (NASDAQ:EXAC) last posted its quarterly earnings results on Monday, October 30th. The medical equipment provider reported $0.20 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.23 by ($0.03). Exactech had a return on equity of 7.22% and a net margin of 0.18%. The company had revenue of $61.40 million during the quarter, compared to analysts’ expectations of $61.78 million. sell-side analysts forecast that Exactech will post 1.29 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This piece was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/02/02/exactech-inc-exac-receives-consensus-recommendation-of-hold-from-analysts.html.
Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.
Receive News & Ratings for Exactech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech and related companies with MarketBeat.com's FREE daily email newsletter.